Current Neurology and Neuroscience Reports

, Volume 5, Issue 4, pp 275–283 | Cite as

The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential

  • K. Ray Chaudhuri
  • L. Yates
  • P. Martinez-Martin
Article

Abstract

Parkinson’s disease (PD) is a progressive disease that usually affects the motor system but is also associated with a non-motor symptom (NMS) complex that ranges from dribbling saliva, constipation, depression, sleep disorders, apathy, hallucinations, and dementia. These features contribute significantly to morbidity and institutionalization, more than quadrupling the cost of care. Furthermore, recent evidence suggests that NMS such as constipation, olfaction, rapid eye movement behavior disorder, fatigue, and depression may be markers of a preclinical stage of PD. PD-NMS are not well recognized in clinical practice and part of the reason is the lack of any instrument that aims to assess the complex range of NMS of PD in a unified and integrated manner. Recently, an international, multidisciplinary PD-NMS group has developed an integrated questionnaire and scale to assess NMS of PD in a comprehensive manner. This will help improve care and treatment of PD in the future.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Parkinson J: An essay on the shaking palsy [reprint of monograph published by Sherwood, Neely, and Jones, London, 1817]. J Neuropsychiatry Clin Neurosci 2002, 14:223–236.PubMedGoogle Scholar
  2. 2.
    Karlsen KH, Larsen JP, Tandberg E, et al.: Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999, 66:431–435.PubMedGoogle Scholar
  3. 3.
    Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson’s disease: a populationbased, prospective study. J Am Geriatr Soc 2000, 48:938–942.PubMedGoogle Scholar
  4. 4.
    Findley L, Aujla MA, Bain PG, et al.: Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 2003, 18:1139–1455. An important cost analysis of the impact of PD on societal and hospitalbased spending in the United Kingdom. Study highlights the cost implication of hospitalization and institutionalization, much of which arises from the emergence of NMS in PD.PubMedCrossRefGoogle Scholar
  5. 5.
    Whetten-Goldstein K, Sloan F, Kulas E, et al.: The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997, 45:844–849.PubMedGoogle Scholar
  6. 6.
    Okun MS, McDonald WM, DeLong MR: Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognised comorbidity. Arch Neurol 2002, 59:807–811.PubMedCrossRefGoogle Scholar
  7. 7.
    Scherder E, Oosterman J, Swaab D, et al.: Recent developments in pain in dementia. BMJ 2005, 330:461–464.PubMedCrossRefGoogle Scholar
  8. 8.
    Gulati A, Forbes A, Stegie F, et al.: A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease. Mov Disord 2004, 19(Suppl 9):S406.Google Scholar
  9. 9.
    Hely MA, Morris JG, Reid WG, Trafficante R: Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190–199. A key study that examines the “real life” symptoms that affect mortality and morbidity in PD, it represents one of the very few longitudinal long-term studies addressing natural history of PD. It addresses the fact that in the long term, NMS of PD appear to affect quality of life and morbidity more than dyskinesias.PubMedCrossRefGoogle Scholar
  10. 10.
    Global Parkinson’s Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002, 17:60–67.CrossRefGoogle Scholar
  11. 11.
    Clarke CE, Zobkiw RM, Gullaksen E: Quality of life and care in Parkinson’s disease. Br J Clin Pract 1995, 49:288–293.PubMedGoogle Scholar
  12. 12.
    Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Nonrecognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002, 8:193–197. Important study that highlights the fact that NMS of PD are not often discussed or flagged during consultations, which are dominated by discussions around motor symptomatology.PubMedCrossRefGoogle Scholar
  13. 13.
    Slaughter JR, Slaughter KA, Nichols D, et al.: Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001, 13:187–196.PubMedGoogle Scholar
  14. 14.
    Grandas F, Iranzo A: Nocturnal problems occurring in Parkinson’s disease. Neurology 2004, 63(Suppl 3):S8-S11.PubMedGoogle Scholar
  15. 15.
    Newman AB, Spiekerman CF, Enright P, et al.: Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group. J Am Geriatr Soc 2000, 48:115–123.PubMedGoogle Scholar
  16. 16.
    Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993, 43:2227–2229.PubMedGoogle Scholar
  17. 17.
    Guttman M, Salughter PM, Theriault ME, et al.: Burden of parkinsonism: A population based study. Mov Disord 2003, 18:313–336.PubMedCrossRefGoogle Scholar
  18. 18.
    Bosanquet N, May J, Johnson N: Alzheimer’s disease in the United Kingdom. Burden of disease and future care. In Health Policy Review Paper No. 12. London: Health Policy Unit, Imperial College School of Medicine; 1998.Google Scholar
  19. 19.
    Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ: Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002, 17:867–876.PubMedCrossRefGoogle Scholar
  20. 20.
    Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease: The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003, 18:738–750. Recognition that the ubiquitous UPDRS does not cover some important aspects of the symptom complex of PD—namely the NMS. Perhaps the time has come for UPDRS to be amended to include the NMS.CrossRefGoogle Scholar
  21. 21.
    Dodel RC, Dubois B, Fahn S, et al.: Addressing non-motor impairments in Parkinson’s disease: the new version of the UPDRS. Mov Disord 2005, 20(Suppl 10):S83 (P 277).Google Scholar
  22. 22.
    Marinus J, Visser M, van Hilten JJ, et al.: Development of a questionnaire for sleep and sleepiness in Parkinson’s disease. Sleep 2003, 26:1049–1054.PubMedGoogle Scholar
  23. 23.
    Marinus J, Visser M, Martinez-Martin P, et al.: A short psychosocial questionnaire for patients with Parkinson’s disease: the SCOPA-PS. J Clin Epidemiol 2003, 56:61–67.PubMedCrossRefGoogle Scholar
  24. 24.
    Visser M, Marinus J, Stiggelbout AM, van Hilten JJ: Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPAAUT. Mov Disord 2004, 19:1306–1312.PubMedCrossRefGoogle Scholar
  25. 25.
    Chaudhuri KR, Martinez-Martin P, Schapira AH, et al.: An international multicentre study validating the first screening questionnaire for comprehensive assesment of non motor symptoms of Parkinson’s disease. Mov Disord 2005, 20(Suppl 10):S50.Google Scholar
  26. 26.
    Isaacson SH: Non-motor symptoms frequently herald end-ofdose wearing off in Parkinson’s disease. Mov Disord 2005, 20(Suppl 10):S52.Google Scholar
  27. 27.
    Stacy M: An abbreviated wearing off patient questionnaire (WOPQ): sensitivity analysis. Mov Disord 2005, 20(Suppl 10):S117.Google Scholar
  28. 28.
    Ross W, Petrovitch H, Abbott RD, et al.: Association of olfactory dysfunction with risk of future Parkinson’s disease. Mov Disord 2005, 20(Suppl 10):S129.Google Scholar
  29. 29.
    Abbott RD, Ross GW, White LR, et al.: Excessive daytime sleepiness and the future risk of Parkinson’s disease. Mov Disord 2005, 20(Suppl 10):S101.Google Scholar
  30. 30.
    Olson EJ, Boeve BF, Silber MH: Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000, 123:331–339.PubMedCrossRefGoogle Scholar
  31. 31.
    Schenck CH, Bundlie SR, Mahowald MW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388–393.PubMedGoogle Scholar
  32. 32.
    Abbott RD, Petrovitch H, White LR, et al.: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57:456–462.PubMedGoogle Scholar
  33. 33.
    Ahlskog JE: Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord 2005, 20:271–282.PubMedCrossRefGoogle Scholar
  34. 34.
    Appiah-Kubi L, Pal S, Chaudhuri KR: Restless legs syndrome (RLS), Parkinson’s disease and sustained dopaminergic therapy for RLS. Sleep Med 2002, 3:S51-S55.PubMedCrossRefGoogle Scholar
  35. 35.
    Parent A, Hazrati LN: Functional anatomy of the basal ganglia. 1. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Review 1995, 20:91–127.CrossRefGoogle Scholar
  36. 36.
    Karachi C, Yelnki J, Tande D, et al.: The pallidosubthalamic projection: an anatomical substrate for non motor functions of the subthalamic nucleus in primates. Mov Disord 2005, 20:172–180.PubMedCrossRefGoogle Scholar
  37. 37.
    Del Tredici K, de Vos R, Rueb U, et al.: Pathoarchitectonic staging of sporadic Parkinson’s disease brains. Mov Disord 2005, 20(Suppl 10):S4.Google Scholar
  38. 38.
    Chaudhuri KR: Nocturnal symptom complex in PD and its management. Neurology 2003, 61(Suppl 3):S17-S23.PubMedGoogle Scholar
  39. 39.
    Diederich NJ, Goetz CG, Stebbins GT: Repeated visual hallucinations in Parkisnon’s disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov Disord 2005, 20:130–140. Paper discussing intriguing new models attempting to explain the phenomenon of visual hallucinations in PD.PubMedCrossRefGoogle Scholar
  40. 40.
    Chaudhuri KR, Pal S, DiMarco A, et al.: The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002, 73:629–635. The first study to address the multifactorial nature of sleep dysfunction, a major NMS in PD, and to devise and validate the first bedside clinical scale to assess sleep dysfunction in PD in a comprehensive manner.PubMedCrossRefGoogle Scholar
  41. 41.
    Martinez-Martin P, Salvador C, Menedez-Guisasola L, et al.:Parkinson’s disease sleep scale: validation study of a Spanish version. Mov Disord 2004, 19:1226–1232.PubMedCrossRefGoogle Scholar
  42. 42.
    Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540–545.PubMedGoogle Scholar
  43. 43.
    Hobson DE, Lang AE, Martin WR, et al.: Excessive daytime sleepiness and sudden onset sleep in Parkinson’s disease: a survey by the Canadian Movement Disorders group. JAMA 2002, 287:455–463.PubMedCrossRefGoogle Scholar
  44. 44.
    Herlofson K, Larsen JP: Measuring fatigue in patients with Parkinson’s disease-the fatigue severity scale. Eur J Neurol 2002, 9:595–600.PubMedCrossRefGoogle Scholar
  45. 45.
    Brown RG, Dittner A, Findley L, Wessley SC: The Parkinson fatigue scale (PFS-16): the development of a new disease specific instrument for use in research and clinical practice. Mov Disord 2004, 19(Suppl 9):S404.Google Scholar
  46. 46.
    Mahieux F, Michelet D, Manifacier MJ, et al.: Mini-mental Parkinson: first validation study of a new bedside test conducted for Parkinson’s disease. Behav Neurol 1995, 8:15–22.Google Scholar
  47. 47.
    Zigmond AS, Snaith RP: The hospital and anxiety and depression scale. Acta Psychiatrica Scand 1983, 67:361–370.Google Scholar
  48. 48.
    Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56–62.PubMedCrossRefGoogle Scholar
  49. 49.
    Peto V, Jenkinson C, Fitzpatrick R, Greenhall R: The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995, 4:241–248.PubMedCrossRefGoogle Scholar
  50. 50.
    Welsh M, McDermott MP, Holloway RG, et al.; Parkinson Study Group: Development and testing of the Parkinson’s disease quality of life scale. Mov Disord 2003, 18:637–645.PubMedCrossRefGoogle Scholar
  51. 51.
    De Boer AG, Wijker W, Speelman JD, De Haes JC: Quaity of life in patients with Parkinson’s disease: development of a questionnaire. J Neurol Nerosurg Psychiatry 2002, 158:41–50.Google Scholar
  52. 52.
    Chaudhuri KR, Schapira AH, Martinez-Martin P, et al.: The holistic management of Parkinson’s using a novel non motor symptom scale and questionnaire. Adv Clin Neurosci Rehab 2004, 4:20–24.Google Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • K. Ray Chaudhuri
    • 1
  • L. Yates
  • P. Martinez-Martin
  1. 1.Neurology, Kings College HospitalLondonUK

Personalised recommendations